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Abstract
Background: Despite recommendations that 11–12-year-olds receive the full three-shot Human papillomavirus (HPV)
vaccine series, national HPV immunization coverage rates remain low. Disparities exist, with Blacks and Latinos being
less likely than Whites to complete the series. We aimed to identify and compare barriers to HPV immunization
perceived by healthcare providers, Black and Latino adolescents, and their caregivers to inform a clinic-based
intervention to improve immunization rates.
Methods: We conducted semi-structured interviews between March and July 2014 with Black and Latino
adolescents (n = 24), their caregivers (n = 24), and nurses (n = 18), and 2 focus groups with 18 physicians recruited
from two pediatric primary care clinics. Qualitative protocol topics included: general perceptions and attitudes
towards vaccines; HPV knowledge; and perceived individual and systems-level barriers affecting vaccine initiation
and completion.
Results: Themes were identified and organized by individual and systems-level barriers to HPV immunization.
Adolescents and their caregivers, particularly Blacks, expressed concerns about HPV being an untested, “newer”
vaccine. All families felt they needed more information on HPV and found it difficult to return for multiple visits
to complete the vaccine series. Providers focused on challenges related to administering multiple vaccines
simultaneously, and perceptions of parental reluctance to discuss sexually transmitted infections.
Conclusions: Optimizing HPV immunization rates may benefit from a multi-pronged approach to holistically
address provider, structural, and individual barriers to care. Further research should examine strategies for
providing multiple modalities of support for providers, including a routinized system of vaccine promotion and
delivery, and for addressing families’ concerns about vaccine safety and efficacy.
Keywords: HPV immunization, Adolescents, Parental preferences, Provider preferences, Qualitative methods
Background
Human papillomavirus (HPV) infection is the most com-
mon sexually transmitted infection (STI) in the United
States (U.S.), and each year, an estimated 26,000 new
cancers attributable to oncogenic HPV are diagnosed in
women and men [1]. Recent U.S. population-based studies
conducted by the Centers for Disease Control and
Prevention (CDC) show that 66 % of cervical cancers,
55 % of vaginal cancers, 79 % of anal cancers, and 62 % of
oropharyngeal cancers are attributable to oncogenic HPV
types 16 or 18 [2]. Disparities exist, with higher rates of
HPV-associated cancers among American Indian/Alaskan
Native, Black, and Latina women than among Whites [3].
National HPV immunization coverage rates remain
remarkably low, despite recommendations from the
Advisory Committee on Immunization Practices and the
American Academy of Pediatrics to routinely provide
immunization of girls and boys aged 11 or 12 years [4–6],
starting in 2006 for girls and 2011 for boys. Available HPV
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vaccines are provided in a 3-dose series [7–12]. In mid-
2014, only 57.3 % of girls aged 13–17 in the U.S. had initi-
ated the three-dose series and only 37.6 % had completed
it, and only 20.8–34.6 % of boys had received ≥1 HPV
dose [13]. These figures are particularly striking when
compared with immunization rates for other adolescent
vaccines (e.g., tetanus, diphtheria, and acellular pertussis
vaccine [Tdap] and meningococcal conjugate vaccine
[MenACWY]), which range from 74.0 % for MenACWY
up to 86.0 % for Tdap [13]. Moreover, Black female adoles-
cents who initiate the vaccine have significantly lower rates
of HPV 3-dose series completion than do White and Latina
female adolescents, and overall rates of immunization re-
main lower among boys than girls [13].
Adolescent vaccines present some distinct challenges
compared to childhood vaccines, including the fact that
adolescents may be involved in decision-making, in
addition to caregivers and providers [14–16]. There are
also specific challenges for HPV immunization, including
its association with adolescent sexual activity and STI ac-
quisition [17], the lack of a school requirement [18], and
misperceptions about vaccine efficacy and safety [19].
Recent research has shown that provider recommen-
dations and communication with caregivers are an
essential step in HPV vaccine uptake and completion
[20, 21]. Yet, few studies to date have focused on under-
standing how perceived barriers to HPV vaccination by
race may reduce uptake. Data are critical to providing
information to optimize effective multi-tiered interven-
tions, in order to achieve the goal of Healthy People
2020, which is to reach an HPV vaccination rate of 80 %
of adolescents aged 13–15 years by 2020 [13, 22]. There-
fore, we conducted a qualitative study of Black and
Latino caregiver-adolescent dyads, as well as their
pediatric healthcare providers, to assess their perspective
on barriers to HPV immunization and the impact of
these barriers on uptake of the vaccine. Our goal was to
use the findings to inform development of an evidence-
based intervention to improve HPV immunization rates
among adolescent boys and girls. In addition, we per-
formed a concordance analysis to compare the extent to
which caregiver-adolescent pairs agreed about their
perceptions of the HPV vaccine.
Methods
Study site
We performed a qualitative study between March and July
2014, using focus groups with physicians and nurse practi-
tioners and semi-structured interviews with nurses, par-
ents and other caregivers (will be referred to as caregivers
henceforth), and adolescents who accessed care at either
of two clinics. One is housed on the campus of a children’s
hospital and cares for over 14,000 young people, drawing
mostly from Boston’s low-income neighborhoods (65 %
are Medicaid beneficiaries). It serves a racially and ethnic-
ally diverse population of patients, who are 45 % Black,
45 % Latino, and 10 % White. In addition, 15 % are non-
English-speaking. The other is a community health center
that provides cares for over 4,000 pediatric patients, drawn
primarily from the surrounding low-income communities
and other similar communities where prior local residents
have moved. Eighty percent are Medicaid beneficiaries.
The patients are 70 % Latino, 20 % Black, and 10 % White,
with many recent immigrants (e.g., Dominican) and refu-
gees (e.g., Somali). It primarily serves a Spanish-speaking
population.
Both clinics use the same advanced electronic health re-
cords. As of September 2013 (the date when funding was
received for this study), 62 % of patients had received at
least one dose of the HPV vaccine by their 13th birthday
(females 73 % and males 49 %), and 23 % had completed
the three-dose series (females 35 % and males 9 %).
Sampling and recruitment
We performed 24 semi-structured interviews with
adolescent-parent pairs (totaling 48 individual inter-
views). We used a purposive sampling strategy to ensure
adequate representation of Black and Latino families
[23]; specifically, we selected a sample of adolescents
split between Black and Latino background, the two
dominant groups in the clinics. Within each group, we
chose a random sample of potential participants, strati-
fied by gender and the number of vaccine doses com-
pleted (0, 1, or 2), to ensure we engaged with a diverse
array of participants. Forty-three percent of those
approached agreed to participate in this study. We also
interviewed 18 nurses and conducted 2 focus groups
with 18 physicians and a nurse practitioner in order to
gain an understanding of how the HPV vaccine was be-
ing offered to adolescent patients and their caregivers
and of what strategies might be effective to increase
vaccination rates.
Eligibility criteria
Adolescents were eligible if they were 12–17 years-old,
were a patient at either of the two study sites, and had
completed zero, one, or two doses of the HPV vaccine
series. Caregivers were eligible if their adolescent child
was participating and they accompanied the adolescent.
Adolescents provided written assent and caregivers pro-
vided written informed consent. All healthcare providers
who worked at the sites were eligible to participate; they
provided oral consent.
Data collection and preparation
Data were collected via semi-structured, 30–60 min in-
depth interviews with adolescents and caregivers, and
two 60-min focus groups with healthcare providers.
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Caregivers and adolescents were each provided $50 for
their participation. Both the semi-structured interviews
and focus groups were designed to elicit information
about perceived parent and patient barriers to HPV
immunization and potential intervention components to
address these barriers. The parent and adolescent proto-
cols additionally included questions to assess knowledge
about HPV and the HPV vaccine, while providers were
questioned about their perceptions of patients’ and
parental knowledge.
Qualitative protocol topics included: (1) General per-
ceptions and attitudes towards vaccines; (2) HPV know-
ledge; (3) Perceptions of the HPV vaccine; (4) Perceived
systems-level barriers and facilitators affecting vaccine
uptake and adherence; and (5) Perceived individual-level
barriers and facilitators affecting vaccine uptake and ad-
herence (see Table 1). A trained research assistant
conducted interviews in English or Spanish, based on
participant preference (half of the interviews with the
Latino caregivers were conducted in Spanish). All inter-
views were audio-recorded (with permission), and were
transcribed and translated into English as necessary.
Conceptual framework
Members of our team developed a conceptual model to
guide socio-behavioral research on HPV vaccination
uptake and completion [24]. This theoretical framework,
titled ‘The Vaccine Perceptions, Acceptability and
Adherence Model,’ is based on a systematic review of the
literature, and provided the basic theoretical framework
for our qualitative protocol. The constructs in this
model – including perceived risk, perceived effectiveness
of the vaccine, perceived barriers to vaccine uptake and
completion, and cues to action (situational factors that
trigger one to get vaccinated or adhere to a vaccine regi-
men) – have been previously shown to be important
predictors of vaccination [24]. The model provides an
integrated and dynamic framework that recognizes cul-
tural and economic forces at play in settings of economic
adversity. The model recognizes the dynamic exchanges
among patients, their caregivers, and their providers, that
are necessary for vaccine-related decision-making. Based
on this model, we developed our qualitative interview
guide, using open-ended questions that allowed for
inductive analyses.
Data analysis
Four team members (ITK, LMB, CMF, and YL) served
as coders and began an inductive analysis with a detailed
review of all transcripts. We used a 3-stage analytic
strategy with open and axial coding, followed by select-
ive coding, to reflect relationships among codes [25].
We developed a codebook, organized according to the
hierarchy developed through axial coding, as part of our
deductive phase of coding. For this phase, we were guided
by our research question. We used Dedoose Version
5.0.11 web application for managing, analyzing, and pre-
senting our qualitative research data (2014, Los Angeles,
CA: SocioCultural Research Consultants, LLC, www.de-
doose.com). We assigned labels to each category and iden-
tified illustrative quotes from interview transcripts. We
ensured trustworthiness of the data by having two authors
independently code the same 20 % of transcripts (CMF,
YL). Inter-rater consistency was very good on all major
themes (ranging between 71.8 % and 84.6 %) [26]. We
then examined the distribution of themes within and
among participant groups, by comparing and contrasting
stakeholder groups – specifically providers, caregivers,
and adolescents.
A primary goal of the study was to understand rela-
tionships between caregivers’ and adolescents’ views on
the HPV vaccine. To do this, we performed a concord-
ance analysis [27, 28] to reflect the match between par-
ental and adolescent perceptions. Concordance analyses
were conducted across themes that had a finite number
of response choices and that were asked of nearly all
caregivers and adolescents. We then identified illustra-
tive quotes to support these findings.
Results
Eighty-four individuals participated (24 caregivers, 24
adolescents, 18 doctors, and 18 nurses). Adolescent and
caregiver participants are described in Table 2. Ninety-
two percent of the caregivers were parents (22/24) and 2
were grandmothers. Themes were identified and orga-
nized by individual-level barriers and systems-level bar-
riers to HPV immunization. Within each barrier type,
we compared perceptions among providers, adolescents,
and their caregivers to assess for differences among
stakeholders and across racial/ethnic groups. Themes
identified in our analyses are detailed below, with quotes
in Tables 3 and 4. Experiences were generally consistent
across the two clinical settings.
Individual-level factors
Overview
Two individual-level barriers to care emerged in the
data: mistrust of vaccines, and lack of education about
vaccine efficacy and safety. Vaccine mistrust was a com-
mon theme among Black adolescents and their care-
givers, who expressed concerns about HPV being a
“newer” vaccine and potentially untested. Families also
felt they needed more education from providers on the
importance of HPV immunization; however, providers
were often reluctant to discuss the vaccine in detail due
to perceived concerns about the sexual association of
the virus.
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Table 1 Qualitative protocol for understanding attitudes and experiences with the HPV vaccine
Patients and Parents (Semi-Structured Interviews) Providers (Focus Groups)
Question topic Question example Question Example
Patients and Parents
General perceptions and attitudes
towards vaccines
Providers
Perceptions of patient/parent
perceptions
• How do you feel about vaccines in general?
• To what extent do you think that vaccines are
helpful (or effective)? Do you think that some
vaccines are more helpful or effective than others?
If so, which ones?
• To what extent do you think that vaccines are harmful
(or ineffective)? Do you think that some vaccines are
more harmful than others? If so, which ones?
• Whom do you trust to give you information about
vaccines in general?
• Whom do you usually go to first when you have
questions about vaccines, and why? (Probe for people
you know, from healthcare providers, from others,
and from the internet or media)
• How much do you think parents and
adolescent patients trust or do not trust the
HPV vaccine to protect adolescents’ health?
• What types of concerns have parents
[adolescents] said to you about the HPV
vaccine? What types of positive feedback have
you heard?
Patients and Parents
Assessment of HPV knowledge
Providers
Assessment of patients’ and
parental knowledge
• Tell me what comes to mind when you hear “HPV?”
• How is HPV prevented, if at all?
• How did you learn about HPV?
• Which sources were most helpful? Least helpful?
• To what extent do you think they think that
the HPV vaccine is harmful, or ineffective? To
what extent do they think it is safe or effective?
• To what extent do you think they think that
the HPV vaccine is necessary?
• To what extent do you think they think that
the HPV vaccine does or does not have side
effects?
• To what extent do you think they think that
the HPV vaccine does or does not cause
discomfort when or after it is administered?
• To what extent do you think they think that
the vaccine does or does not cause teens to
have sex?
• To what extent do you think they think that
the HPV vaccine is helpful (or effective)?
• To what extent do you think that they know
that the HPV vaccine prevents cancer? Prevents
STIs?
Patients and Parents
Perceptions of the HPV vaccine
Providers
Perceptions of how patients and
parents view the HPV vaccine
• How much do you trust or not trust the HPV vaccine?
Why or why not?
• To what extent are you willing or not willing to vaccinate
your child(ren) for HPV?
• To what extent do you think that the HPV vaccine is
necessary or not necessary for boys? For girls?
• To what extent do you think that the HPV vaccine is
harmful or ineffective?
• From whom or where have you heard information about
the HPV vaccine?
• To what extend do you believe what you have heard
about the HPV vaccine?
• From whom or where do you think your child gets
information about HPV?
• How do patients and parents react to the idea
of the HPV vaccine?
• What kinds of things do parents typically
say when you bring up the vaccine?
• What kinds of questions do parents ask?
• How are these questions addressed? By
whom?
• What types of reasons do patients and parents
give when declining the vaccine?
• How do you respond when parents decline
for their adolescent to get the vaccine?
• In general, how do you address a situation
where a parent declines? What do you say?
Patients and Providers
Perceived systems-level factors
affecting vaccine uptake and
adherence
Providers
Perceptions of provision of care
and systems-level factors influencing
vaccine uptake and adherence
• If you have not received the vaccine, what factors played
a role?
• What factors related to you, your child, or your healthcare
provider played a role?
• How much do you intend to get the 2nd and 3rd shots for
your child?
• What kinds of things might be a barrier to your child
coming back to get the 2nd and 3rd shots?
• What kinds of things might be helpful in getting your
child back for the 2nd and 3rd shots?
• What kinds of things do you think that the
clinic does particularly well and what kinds of
things do you think that the clinic does less
well in getting adolescents to take the HPV
vaccine?
• Why do you think that things work that way in
the clinic?
• What kinds of things might be a barrier to
adolescent patients coming back to get the 2nd
and 3rd shot?
• What kinds of things might be helpful in
getting adolescent patients back for the 2nd
and 3rd shots?
• What kinds of things can healthcare providers
and clinics do to help get more children
vaccinated for HPV?
• What kinds of information could healthcare
providers give to parents about the vaccine?
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1) Mistrust:
Adolescent and caregiver perceptions. Black
caregivers discussed their mistrust of vaccine safety
in general, with less focus on the HPV vaccine in
particular. Caregivers who expressed mistrust of
vaccines tended to speak about “newer” vaccines
being less trustworthy than vaccines that they
received in their childhood (Table 3, Row 1), and the
risk of “experimentation” on their children (Table 3,
Row 2). While adolescents had less mistrust of
vaccines, they acknowledged a generalized fear of
vaccines related to potential pain from an injection.
This view was not specific to the HPV vaccine
(Table 3, Row 3). In particular, individuals who had
not yet received the vaccine tended to discuss the
role of mistrust in leading them to avoid vaccination,
as compared to those who had initiated the series.
2) Lack of education:
Adolescent and caregiver perceptions. Adolescents
and caregivers believed that they lacked adequate
information to make informed decisions about the
vaccine. In particular, parents of boys spoke
frequently about their mistaken belief that boys
needed vaccination only to protect potential future
female partners. Caregivers reported that nurses and
physicians did not provide adequate explanations of
Table 1 Qualitative protocol for understanding attitudes and experiences with the HPV vaccine (Continued)
• How should healthcare providers communicate
with parents to let them know about the
vaccine?
• What would help parents and adolescents
initiate the vaccine series?
• What would help parents and adolescents
complete the vaccine series?
• What kinds of things can the clinic do to help
remind parents about the 2nd and 3rd doses of
the vaccine?
• What methods of communication reminders
would be most helpful (email, texts, phone,
etc.)?
Patients and Parents
Perceived individual-level factors
affecting vaccine uptake and
adherence
Providers
Perceptions offering the HPV vaccine
• What kinds of questions and concerns did you have
about the HPV vaccine when it was first introduced to
you by the clinic staff?
• What kinds of questions and concerns did your child
have?
• To what extent were your and your child’s concerns
addressed or not addressed? If yes, how and by
whom, and with what information? If no, why do you
feel that your concerns were not addressed?
• If you did receive the vaccine, how was it decided that
you would get the HPV vaccine?
• How do you discuss HPV with adolescent
patients and their parents?
• What factors influence your decision to offer
the HPV vaccine to an adolescent and parent
of an adolescent patient?
• How do you present information about the
HPV vaccine to patients and parents?
• What kind of things do you typically
discuss with adolescents about the HPV
vaccine?
• When offering the vaccine, to what extent
do you talk to the adolescent?
Patients and Parents
Feedback on proposed intervention
Providers
Feedback on proposed intervention
• What kinds of things can healthcare providers and clinics
do to help get more children vaccinated for HPV?
• What do you think about the following intervention
components:
• Text message reminders for follow-up visits?
• Educational materials like pamphlets and videos?
• Computer systems to track patients who do and do
not initiate and complete the vaccine?
• Tracking whether physicians are offering and giving
the vaccine, and giving them feedback about how
they are doing?
• Provider reminders about patients who are due to
start the vaccine series or receive another dose?
• Teaching healthcare providers how to communicate
with patients who refuse the vaccine?
• What kinds of things can healthcare providers
and clinics do to help get more children
vaccinated for HPV?
• What do you think about the following
intervention components:
• Text message reminders for follow-up
visits?
• Educational materials for parents and
adolescents like pamphlets?
• Computer systems to track adolescent
patients who do and do not initiate and
complete the vaccine?
• Tracking whether physicians are offering
and giving the vaccine, and giving them
feedback about how they are doing?
• Implementing and using a quality measure
of clinic and physician HPV vaccination
rates?
• Provider reminders in the electronic health
record about adolescent patients who are
due to start the vaccine series or receive
another dose?
• Teaching healthcare providers how to use
supportive communication strategies to
address vaccine refusal?
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the vaccine’s safety and efficacy to allow families
to make informed decisions. Caregivers and
adolescents were often uncertain about whether
they needed to come back to complete the series
(Table 3, Rows 4 and 5).
Healthcare provider perceptions. Healthcare
providers discussed concerns that they had about
discussing the HPV vaccine, given its association
with an STI (Table 3, Row 6). Although all
physicians recognized the importance of the HPV
vaccine, many perceived caregiver resistance to the
vaccine and thought it was likely due to concerns
about promoting sexual intercourse. Providers
sometimes acknowledged that they deferred
potentially challenging conversations about the
vaccine to subsequent visits.
Systems-level factors
Overview
We identified three systems-level barriers to care in the
qualitative data: challenges associated with the dosage
schedule, lack of standardization of delivery and reminder
process, and administration of multiple vaccines at the
same visit.
1) Challenges associated with the dosage schedule:
Healthcare provider perceptions. Both physicians
and nurses discussed the challenges in requiring
adolescents to return for the second vaccination
at 2 months and the third vaccination at
6 months after the first dose because the timing
did not match other standard clinical visits
(Table 3, Row 7). Providers felt this resulted in
large numbers of adolescents who had not
completed all 3 doses of the vaccine.
2) Lack of routinization:
Healthcare provider perceptions. Providers described
feeling burdened with checklists and reminders
about many elements of healthcare maintenance,
and the challenge to monitor HPV series
completion. This concern was often discussed in
association with the need for an increased number
of support staff to facilitate communication and
collaboration, and a lack of system-level reminders.
Physicians found themselves relying on nurses to
help remind them to offer the HPV vaccine, or to
initiate a dialogue with patients and caregivers.
Many physicians and nurses described having inad-
equate time in a clinic visit to address all the needs
of their patients (Table 3, Row 8).
3) Administration of Multiple Vaccines at the same
visit:
Healthcare provider perceptions: Many providers
described concerns about the number of vaccines
being administered to eleven-year-olds. Physicians
noted that there are already two standard vaccines
given at that visit (Tdap and MenACWY) and a
“third shot will put the kids at that age over the
edge,” on top of yet another vaccine (the influ-
enza vaccine) during several months of the year.
Some nurses, though, felt that a third vaccine
could be incorporated into an annual visit in a
manner that would not pose additional challenges
(Table 3, Row 9). Concerns about receiving
multiple vaccines simultaneously did not factor
prominently in the interviews of caregivers and
adolescents.
Caregiver-adolescent concordance analysis
We identified three themes through our concordance
analysis: Lack of education, mistrust, and association
Table 2 Adolescent and Caregiver Participants (n = 48)
Characteristic Blacka Latinoa P-value
Caregivers
Age 0.803
Mean (SD) 40.44 (13.62) 39.14 (8.61)
Range 31-75 30-59
Education 0.067
Grades 1-6 0 2
Grades 7-11 1 1
High school graduate 1 6
Some college, no degree 6 1
College degree 2 2
Some graduate 0 1
Graduate degree 1 1
Marital status 0.869
Single 5 5
Married 4 7
Partner 2 2
Adolescents 1
Gender
Female 6 7
Male 6 7
Age 0.331
Mean (SD) 13.67 (1.61) 13.07 (1.44)
Range 12-16 12-16
Series status 0.549
0 doses 7 6
1 dose 3 7
2 doses 1 1
3 doses 1 0
aOne parent and two adolescents identified as Black and Latino. Numbers are
reflected accordingly in the table
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with pain. Caregivers and adolescents were consistently
concordant within dyad in discussing how they lacked
information and adequate education on the HPV vac-
cine, which often translated into a reluctance to accept
the vaccine when offered (Table 4, Row 1). In addition,
caregivers and adolescents in the same dyad consistently
stated that they mistrusted the vaccine, which was cited
as a reason both for initial refusal of the vaccine and
concerns about returning to complete the 3-shot series
(Table 4, Row 2). Conversely, adolescents were much
more concerned about the potential for pain associated
with the vaccine than were their caregivers. There was
little discussion among either caregivers or adolescents
of the structural barriers cited by providers, including
dosage schedule, lack of routinization, and the number
of vaccines administered at a given visit.
Discussion
Interviews and focus groups with providers and fam-
ilies revealed a broad range of challenges that they
face, respectively, in administering and completing the
HPV vaccine series. Providers primarily focused on
systems-level challenges related to standardization of
vaccine administration, time pressures in the clinic,
and the need to optimize collaboration among pro-
viders. They also discussed their concerns related to
potentially negative perceptions of the vaccine from
caregivers. This led to avoidance of what they antici-
pated to be challenging discussions (e.g., discussing
the transmission of HPV through sexual contact) in
order to cover most age-appropriate issues within
what they described as tight time constraints available
for visits.
Table 3 Individual and Structural-level Barriers to HPV Immunization
Category Row # Participant Representative Quotation
Mistrust
Caregiver perceptions 1 Black caregiver of
an adolescent girl
“Well, the earlier vaccines – the measles and mumps and all that – I am
fine with those… It’s the newer ones that I am not.”
Caregiver perceptions 2 Black caregiver of
an adolescent girl
“We don’t know what’s inside of the vaccines, and they can be harmful if
you don’t know what it is. It might not mix well with bodies and cells. They
should just be more careful. It is like we’re being picked like guinea pigs.”
Adolescent perceptions 3 Latino adolescent boy Interviewer: “Do you trust the vaccine?”
Adolescent: “Not at all…because I don’t know what it does…I never heard
it…it depends how big the needle is.”
Lack of education
Adolescent perceptions 4 Latina adolescent girl “They usually just give you a handout, like a little sheet explaining what it is
and the side effects and what could possibly happen. And so, that is it. I
really don’t know much about it.”
Caregiver perceptions 5 Black caregiver of
an adolescent girl
“I didn’t know that I needed to come back. I had no clue that you had to
give me more than one, and I wasn’t told that at the time.”
Healthcare provider perceptions 6 Physician “With HPV—a lot of them haven’t heard about it… A lot of times I look at
the adolescents and say have you seen those ads on TV—Gardasil? They will
be the ones who recognize it. Their parents, not so much.”
Challenges associated with the dosage schedule
Healthcare provider perceptions 7 Nurse “I think getting them back for their second and third is a real problem. It
would be nice if we had a better system to remind parents… I find that a
lot of times you see them and they get their second [shot] a year later. They
come then because the adolescents only come once a year.”
Lack of Routinization
Healthcare provider perceptions 8 Physician “We’re under the gun in terms of time. So if our primary directive at a visit
is to get these kids up-to-date with immunizations, then the goal is to sort
of get that done with as little conversation and resistance as possible, and
then hopefully you have time to have meaningful conversations about
real-world stuff like with what’s going on with sexual activity or dating or
boyfriends or parent relationships or whatever else the myriad of things that
are going on. So all these conversations that we are having around HPV are
really—we’re just trying to sell it, for lack of a better word. We’re just trying
to get it done so that we can move on to the more meaningful points
of the visit.”
Administration of multiple vaccines at the same visit
Healthcare provider perceptions 9 Nurse “I think that, you know, that offering it to children at eleven and just sort
of matter of fact tell them this is what we do at eleven, along with their
Tdap and their meningococcal vaccine. It works pretty well.”
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Caregivers and adolescents, conversely, rarely mentioned
systems-level barriers to care. In general, most caregivers
and adolescents focused primarily on individual-level bar-
riers, with both groups expressing concern over the lack of
education they received regarding vaccine safety and effi-
cacy. In addition, adolescents discussed fears of potential
pain associated with the vaccine, and caregivers describing
mistrust of the vaccine. Black caregivers, in particular,
expressed concern over HPV being a “newer” vaccine, and
therefore potentially experimental in nature. Mistrust also
appeared to be a barrier to vaccination among those who
had never received the vaccine. Certain constructs identi-
fied through our qualitative research map onto our con-
ceptual model [24]. In particular, patients and their
families expressed the need to weigh the perceived risk of
receiving a vaccine against the perceived effectiveness of
the vaccine. Participants who expressed significant mis-
trust tended to express more concern about the perceived
risk of the HPV vaccine.
Prior literature has suggested an association between
medical mistrust and disparities in a variety of health
outcomes [29–33]. While fewer studies have focused on
understanding the link between medical mistrust and
prevention of STIs, recent research has shown that
women with higher mistrust were less likely to have en-
gaged in preventive health behaviors such as HPV
immunization, a trend that was exacerbated when pa-
tients and providers were racially discordant [34]. This
finding has significant public health implications given
higher rates of HPV prevalence and cervical cancer inci-
dence and mortality and lower rates of HPV vaccine
completion in Black and Latina women, compared to
White women [35–37].
The concordance analyses revealed that both care-
givers and adolescents in the same family were consist-
ent in feeling that they lacked adequate education and
information regarding the vaccine to make sound deci-
sions. Many expressed that this was the primary reason
for not obtaining a shot at a given visit. Caregivers and
adolescents also described how vaccine mistrust factored
into their decision (particularly among caregivers), and
concerns about potential pain associated with the shot
(particularly among adolescents). Overall, families rarely
mentioned structural barriers to vaccination, whereas
providers listed these factors as primary reasons to
avoid administering the vaccine. This is supported by
recent literature showing that primary care providers
often perceive discussions about the HPV vaccine to
be time-consuming and necessitating more parental
engagement than discussions about other mandatory
vaccines [38].
Given these findings, several potential strategies may be
useful for improving rates of HPV vaccine immunization.
Research supports a varied and flexible approach to inter-
vention design, which can be implemented within health-
care settings to increase HPV vaccine uptake across
diverse populations [39]. For example, standardization of
work-flow using electronic health record reminders could
decrease the burden on individual providers. In addition,
longer vaccination appointments could be scheduled to
educate families about what vaccines children should
have, while providing adequate information focused on
vaccine safety, efficacy, and misinformation. Educational
messaging focused on addressing mistrust could poten-
tially incorporate research findings suggesting the HPV
vaccine is not linked to risky sexual behaviors [40].
Table 4 Representative Quotes from Concordance Analysis of Caregiver-Adolescent Dyads
Category Row # Adolescent Caregiver
Lack of education
(concordance)
1 I: “What factors played a role in your decision
not go get the HPV vaccine.”
R: “Umm… me not knowing about it. Not
knowing enough.”
I: “And that’s the only thing was the lack of
information?”
R: “Yeah.”
“Just because like I said, [the physician] could have
given me more information. Then I could’ve read up
on it even if I wasn’t going to let him get it anyway.
So, it wouldn’t have mattered, but still, I would’ve still
wanted to know what it is and I think that that’s the
problem that they create these new vaccines and they
don’t let the parents know about them, read about them
before the scheduled appointment and so when the
appointment comes it’s like no, and this is why I’m
saying no.”
Mistrust (concordance) 2 “Yeah, [my caregiver] talked to the doctor, that’s
why she said, ‘Oh I don’t know if I want [me] to
get it.’ Because there’s a thing that it said it
killed people—whatever.”
“To be honest, death wasn’t something I thought about
a lot. It wasn’t until I just read that article–how true it is,
I don’t know. Supposedly that was the stats that they had,
and there were a lot of deaths in it, among other things.
But I—I think my mind won—because being paralyzed
was one of the other things. [My child] could become
paralyzed, it could be temporary and could be
permanent… It was that part of that, you know
what I mean?”
Association with pain
(discordance)
4 “No, I was just scared of getting it because I
haven’t had a shot in a while, so…”
“Well, my daughter’s first question was, ‘Is it going to
hurt,’ but, other than that, no [problem].”
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This study is subject to a key limitation - all interviews
were conducted with participants from one healthcare
organization, albeit two distinct sites within the system.
Thus, our findings may not be representative of practices
nationwide. The strength of qualitative research, how-
ever, lies in its ability to explore a range of viewpoints
on a given topic, as opposed to ensuring generalizability.
To optimize our potential to engage with a range of indi-
viduals, we recruited our population from a community-
based health center and an academic medical center and
included boys and girls, as well as their caregivers and
providers.
Conclusions
Our findings provide an in-depth examination of the
many barriers to HPV immunization among traditionally
underserved communities and highlight the need to de-
sign interventions that effectively address both structural
and individual barriers to care. Further research could
examine the impact of incorporating multiple modalities
of support for providers, including a routinized system
of vaccine promotion and delivery while addressing fam-
ilies' concerns about vaccine safety and efficacy.
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